Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients

[1]  Jianyin Li,et al.  A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab , 2022, European Radiology.

[2]  Jianyin Li,et al.  A Novel Clinical Radiomics Nomogram to Identify Crohn’s Disease from Intestinal Tuberculosis , 2021, Journal of inflammation research.

[3]  Shen Jun,et al.  Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  S. Suo,et al.  A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease , 2021, Journal of inflammation research.

[5]  Q. Feng,et al.  Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients , 2021, Frontiers in Pharmacology.

[6]  R. Atreya,et al.  Location is important: differentiation between ileal and colonic Crohn’s disease , 2021, Nature Reviews Gastroenterology & Hepatology.

[7]  M. Baker,et al.  Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease. , 2021, Gastroenterology.

[8]  I. Ordás,et al.  Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease , 2020, Alimentary pharmacology & therapeutics.

[9]  G. Kaplan,et al.  Smoking may reduce the effectiveness of anti-TNF therapies to induce clinical response and remission in Crohn's disease: a systematic review and meta-analysis. , 2020, Journal of Crohn's & colitis.

[10]  J. Maul,et al.  Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  E. Savarino,et al.  Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. , 2020, Inflammatory bowel diseases.

[12]  E. Klang,et al.  Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[13]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[14]  F. Magro.  Anti-TNF treatment failure: drug levels, immunogenicity, or both? , 2019, The lancet. Gastroenterology & hepatology.

[15]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[16]  R. Grützmann,et al.  Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease , 2018, Gut.

[17]  Iva Petkovska,et al.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. , 2018, Radiology.

[18]  W. Sandborn,et al.  Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. , 2018, Gastroenterology.

[19]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[20]  Zhenchao Tang,et al.  Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer , 2017, Clinical Cancer Research.

[21]  Stefan Leger,et al.  Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.

[22]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[23]  M. Hull,et al.  Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease. , 2016, Journal of Crohn's & colitis.

[24]  R. Xavier,et al.  Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease , 2016, The American Journal of Gastroenterology.

[25]  N. Ding,et al.  Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.

[26]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[27]  Judy H. Cho,et al.  Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study , 2015, Alimentary pharmacology & therapeutics.

[28]  A. Kühl,et al.  Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD , 2015, Inflammatory bowel diseases.

[29]  G. Veres,et al.  Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease. , 2014, Journal of Crohn's & colitis.

[30]  Wolfgang Uter,et al.  In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.

[31]  J. Schölmerich,et al.  Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data , 2010, The American Journal of Gastroenterology.

[32]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[33]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[34]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[35]  S. Carding,et al.  Inflammatory bowel disease: cause and immunobiology , 2007, The Lancet.